Medicinal chemistry efforts typically focus on drug–protein interactions and overlook RNA binding as a source of off-target pharmacology. Now, a new method has been developed to map the interactions of small-molecule drugs with RNA in cells and characterize how these interactions can exert functional effects.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Falese, J. P. et al. Chem. Soc. Rev. 50, 2224–2243 (2021).
Yazdani, K. et al. Angew. Chem. 135, e202211358 (2023).
Sheridan, C. Nat. Biotechnol. 39, 6–8 (2021).
Zhang, P. et al. J. Am. Chem. Soc. 143, 13044–13055 (2021).
Huang, S. et al. Nat. Commun. 13, 2413 (2022).
Fang, L. et al. Nat. Chem. https://doi.org/10.1038/s41557-023-01309-8 (2023).
Weeks, K. M. Acc. Chem. Res. 54, 2502–2517 (2021).
Bennett, A. C. et al. Expert Opin. Drug Saf. 18, 1055–1063 (2019).
Flynn, R. A. Nat. Protoc. 11, 273–290 (2016).
The authors declare no competing interests.
About this article
Cite this article
Fullenkamp, C.R., Schneekloth, J.S. RNA as an off-target for FDA-approved drugs. Nat. Chem. 15, 1329–1331 (2023). https://doi.org/10.1038/s41557-023-01330-x